Scoring the tumor-stroma ratio in colon cancer: procedure and recommendations

被引：0
作者：
G. W. van Pelt
S. Kjær-Frifeldt
J. H. J. M. van Krieken
R. Al Dieri
H. Morreau
R. A. E. M. Tollenaar
F. B. Sørensen
W. E. Mesker
机构：
[1] Leiden University Medical Center,Department of Surgery
[2] Vejle Hospital,Department of Clinical Pathology
[3] part of Lillebaelt Hospital,Department of Pathology
[4] Radboud University Medical Center,Department of Pathology
[5] European Society of Pathology,Institute of Regional Health Research
[6] Leiden University Medical Center,University Institute of Pathology
[7] University of Southern Denmark,undefined
[8] Aarhus University Hospital,undefined
来源：
Virchows Archiv | 2018年 / 473卷
关键词：
Colon cancer; Protocol; Recommendations; Scoring; Tumor-stroma ratio;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The tumor-stroma ratio (TSR) has been reported as a strong, independent prognostic parameter in colon cancer as well as in other epithelial cancer types, and may be implemented to routine pathology diagnostics. The TSR is an easy technique, based on routine hematoxylin and eosin stained histological sections, estimating the amount of stroma present in the primary tumor. It links tumors with high stromal content to poor prognosis. The analysis time is less than 2 min with a low inter-observer variation. Scoring of the TSR has been validated in a number of independent international studies. In this manuscript, we provide a detailed technical description of estimating the TSR in colon cancer, including examples, pitfalls, and recommendations.
引用
收藏
页码：405 / 412
页数：7
相关论文
共 256 条
[1]  
Nagtegaal ID(2011)Has the new TNM classification for colorectal cancer improved care? Nat Rev Clin Oncol 9 119-123
[2]  
Quirke P(2000)The influence of the microenvironment on the malignant phenotype Mol Med Today 6 324-329
[3]  
Schmoll HJ(2013)The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial Ann Oncol 24 179-185
[4]  
Park CC(2007)The carcinoma-stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumor stage Cell Oncol 29 387-398
[5]  
Bissell MJ(2009)Presence of a high amount of stroma and downregulation of SMAD4 predict for worse survival for stage I–II colon cancer patients Cell Oncol 31 169-178
[6]  
Barcellos-Hoff MH(2011)Tumor-stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients Breast Cancer Res Treat 125 687-696
[7]  
Huijbers A(2013)Prognostic significance of the tumor-stroma ratio: validation study in node-negative premenopausal breast cancer patients from the EORTC perioperative chemotherapy (POP) trial (10854) Breast Cancer Res Treat 139 371-379
[8]  
Tollenaar RA(2017)The prognostic value of the tumour-stroma ratio in primary operable invasive cancer of the breast: a validation study Breast Cancer Res Treat 166 435-445
[9]  
v Pelt GW(2010)The stromal part of adenocarcinomas of the oesophagus: does it conceal targets for therapy? Eur J Cancer 46 720-728
[10]  
Zeestraten EC(2014)Tumor-stroma ratio is an independent predictor for survival in early cervical carcinoma Gynecol Oncol 132 81-86
12345678910